Department of Psychiatry, UMDNJ, Robert Wood Johnson Medical School, D317, 675 Hoes Lane, Piscataway, NJ 08854, USA.
J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):188-95. doi: 10.1176/jnp.2010.22.2.188.
Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.
抑郁与帕金森病认知衰退速度加快有关。本研究的目的是检验抗抑郁药物（8 周急性期和 24 周长期）对帕金森病患者认知的影响，并详细说明认知对治疗反应的预测作用。52 名抑郁的帕金森病患者参与了一项由美国国立卫生研究院资助的关于去甲替林、帕罗西汀和安慰剂的随机对照试验。在基线和第 8 周和第 24 周时进行神经心理学测试。执行功能、处理速度和言语记忆测试的基线分数较高与抗抑郁反应相关。治疗反应者的认知增益并不比无反应者大。研究结果需要进一步证实。
